Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature

BACKGROUND: In patients with advanced hepatocellular carcinoma (HCC), the multikinase inhibitor sorafenib is the only systemic treatment that has been shown to increase overall survival. However, similar to other tyrosine kinase inhibitors, most patients achieve disease stabilisation radiologically,...

Descripción completa

Detalles Bibliográficos
Autores principales: Atkin, Catherine, Earwaker, Philip, Pallan, Arvind, Shetty, Shishir, Punia, Pankaj, Ma, Yuk Ting
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307848/
https://www.ncbi.nlm.nih.gov/pubmed/28193171
http://dx.doi.org/10.1186/s12876-017-0585-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307848/
https://www.ncbi.nlm.nih.gov/pubmed/28193171
http://dx.doi.org/10.1186/s12876-017-0585-x

Ejemplares similares